Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions: PXS-5505; Drug
Lead sponsor: Syntara; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas

Conditions: Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions: Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tardive Dyskinesia
Interventions: SD-809, Placebo; Drug
Lead sponsor: Auspex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 44
States / cities: Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Gastric Cancer
Interventions: S-1/Cisplatin, 5-FU/cisplatin; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 32
States / cities: Huntsville, Alabama • Burbank, California • Gilroy, California + 23 more

Conditions: Current Smoker, Never Smoker, Tobacco Use Disorder, Former Smoker, E-cig User
Interventions: Bronchoscopy, Electronic Cigarette, Laboratory Biomarker Analysis, Questionnaire Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 45 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Participants
Interventions: Brensocatib Oral Solution, Brensocatib Oral Tablet; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Body Dysmorphic Disorder
Interventions: PET scan and MRI scan; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: occupational therapy task-oriented approach, Forearm rotation orthosis, No treatment; Behavioral · Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Interventions: Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depression Scale, Social Support, Brief Test of Attention, Trail Making Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Blood draw; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: ALT-803; Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions: [18F]FP-R01-MG-F2; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: Eltrombopag; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Leukemia
Interventions: rituximab, cyclophosphamide, pentostatin, Alemtuzumab; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 143
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more

Conditions: RRMM
Interventions: Melphalan, Dexamethasone; Drug
Lead sponsor: Oncopeptides AB; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Peer Coaching - Peer Participants A, Peer Coaching - Peer Participants B, Peer Coaching - Peer Participants C, Peer Coaching - Peer Participants D; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Bowling Green, Kentucky • Hazard, Kentucky

Conditions: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Interventions: favezelimab/pembrolizumab, pembrolizumab, lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more

Conditions: AL Amyloidosis
Interventions: CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Cleveland, Ohio

Conditions: Head and Neck Neoplasms
Interventions: Prexasertib, Cisplatin, Cetuximab, Intensity Modulated Radiation Therapy; Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Houston, Texas

Conditions: Crohn's Disease
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 12
States / cities: Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: Type 1 Diabetes
Interventions: AIDANET system; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Dry Eye
Interventions: doxycycline, placebo; Drug
Lead sponsor: Alacrity Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Timeline: 2007
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Mild Traumatic Brain Injury
Interventions: MRI imaging exam; Device
Lead sponsor: The Geneva Foundation; Other
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Fort Belvoir, Virginia

Conditions: Colorectal Neoplasms, Breast Neoplasms
Interventions: Chi gung: Stay Well, Live Well; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: New York, New York

Search by objective public record fields.

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

A Safety and Efficacy Study in Patients With Gastric Cancer

Effects of Electronic Cigarette Use on the Lungs

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

Escitalopram Neuroimaging Supplement

Forearm Rotation Orthosis for Stroke

Study of CAR-T Therapy in Older Patients

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Fully Closed Loop At Home (FCL@Home)

A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period

Acute and Mild TBI Injury in Military and Civilian Population Using Advanced MR Imaging

Increasing Breast and Colorectal Cancer Screening in the Community